Compare Datadog Inc (DDOG) vs ResMed Inc. (RMD) Price & Performance

Datadog (DDOG) trades at $244.2, down 6.36% over 24 hours, with a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. Revenue grew 36% year-over-year to $1.12 billion, but the stock faces pressure from high valuations (P/E 493.56) and concerns over a major customer's reduced usage. Analyst consensus remains strongly bullish with an 83.34% buy rating and a $288.55 price target, suggesting significant upside potential from current levels.

The outlook is mixed: robust fundamentals and AI-driven growth support long-term value, but near-term volatility persists due to premium valuation and investor skepticism post-earnings. Key risks include customer concentration, competitive pressures, and execution challenges in sustaining high growth rates. Investors should weigh strong analyst conviction against technical weakness and market sentiment shifts.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.